Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Wilex Biotechnology Gmbh

Friedrich-alexander-universitat Erlangen-nürnberg

Suppremol Gmbh

Chiara Cabrele

Uwe Jacob

Kerstin Wendt

Peter Sondermann

Luis Moroder

Robert Huber

Olaf G Wilhelm

Viktor Magdolen

Stefan Sperl

Wolfram Bode

Joerg Stuerzebecher

Nuria Arroyo De Prada

Thomas Pohl

Peter Buckel

Dominik Ter Meer

Karl-Peter Hopfner

Nadja Fenn

Sarah Wildenhain

Claudia C Roskopf

Todd Braciak

Georg H Fey

Ingo Schubert

Reno Winter

Sarah Wildenhein

Claudia Christina Roskopf

Cabrele Chiara

The present invention relates to a nucleic acid molecule encoding a chain myeloid capable of specifically binding to CD33, CD16 and CD123, wherein said nucleic molecule comprises: (a) a nucleic add molecule encoding a protein represented by SEQ ID NO:1; (b) a nucleic acid molecule represented by SEQ ID NO:2; (c) the nucleic add molecule of (b), wherein each thymine is replaced by urea; (d) a nucleic acid molecule encoding a protein having at least 98% sequence identity to the protein of (a); or (e) a nucleic add molecule that is degenerate with respect to the nucleic acid molecule of (b) or (c). The present invention further relates to a vector comprising the nucleic acid molecule of the invention, a host cell transformed or transfected with the nucleic acid molecule or the vector of the invention, as well as to a method for the production of a single chain myeloid capable of specifically binding to CD33, CD16 and CD123. Furthermore, the present invention also relates to a single chain myeloid capable of specifically binding to CD33, CD16 and CD123 encoded by the nucleic acid molecule of the invention, as well as to a composition comprising the nucleic acid molecule, the vector, the host cell and/or the single chain myeloid of the invention. Also, encompassed by the present invention are the nucleic acid molecule, the vector, the single chain myeloid and/or the composition of the invention for use in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome, as well as a method of treating acute myeloid leukaemia and/or myelodysplastic syndrome.

CD33-, CD16- and CD123-specific single chain triplebody

The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.

Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc&#x3b3;RIIb or Fc&#x3b3;RIIa.

Substance binding human IgG Fc receptor IIb (Fc&#x3b3;RIIb)

Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies.

Recombinant soluble FC receptors

Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.

Recombinant soluble Fc receptors

A method is described for inhibiting urokinase plasminogen activator in a human or animal patient. The method involves administering to the patient a urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I): 

Highly selective inhibitors of the urokinase plasminogen activator

The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.

Growing community of inventors

Munich, Germany

Uwe Jacob